| Literature DB >> 32273707 |
Xiao-Ling Liao1, Li-Jun Zuo1, Ning Zhang2, Yang Yang2, Yue-Song Pan3, Xiang-Long Xiang3, Ling-Yun Chen4, Xia Meng3, Hao Li3, Xing-Quan Zhao1, Yi-Long Wang1, Chun-Xue Wang2, Jiong Shi3, Yong-Jun Wang1.
Abstract
BACKGROUND ANDEntities:
Keywords: cognitive impairment; ischemic stroke; longitudinal cohort study; occurrence
Year: 2020 PMID: 32273707 PMCID: PMC7114937 DOI: 10.2147/NDT.S234544
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Figure 1The geographical locations of participating hospitals in the ICONS.
Figure 2Flow chart of patient enrollment in the study. There were 2704 patients who were screened and consented from 40 participating sites. Finally, a total of 2432 acute ischemic stroke patients were included for this study.
Baseline Demographic Characteristics, Medical History and Stroke Subtype
| Baseline Variables | AIS n(%) N=2432 |
|---|---|
| Gender male | 1774(72.94) |
| Average age (years) | 60.95±10.78 |
| Race (Han) | 2351(96.67) |
| Education level | |
| Elementary or below | 638(26.23) |
| Middle school | 867(35.65) |
| High school or above | 809(33.26) |
| Unknown | 118(4.85) |
| Current smoker | 890(36.60) |
| Secondhand smoking | 385(15.83) |
| Heavy drinker (>60g/d) | 154(6.33) |
| Medical History | |
| Diabetes | 562(23.11) |
| Hypertension | 1530(62.91) |
| Lipid metabolism disorders | 234(9.62) |
| Cerebral infarction | 509(20.93) |
| ICH | 32(1.32) |
| Subarachnoid hemorrhage | 4(0.16) |
| TIA | 64(2.63) |
| Heart failure | 9(0.37) |
| Atrial fibrillation | 72(2.96) |
| Carotid artery stenosis | 15(0.62) |
| Epilepsy | 7(0.29) |
| Sleep Apnea | 29(1.19) |
| Median NIHSS score (IQR) | 3(1–5) |
| Stroke subtype for TOAST | |
| Large artery atherosclerosis | 1407(57.85) |
| Cardiogenic embolism | 99(4.07) |
| Small artery occlusion | 768(31.58) |
| Other/Unknown | 158(6.50) |
| Median Stroke onset to enrollment time (day) | 1(0–2) |
Abbreviations: ICH, Intracranial Cerebral Hemorrhage; TIA, Transient Ischemic Attack; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; TOAST, the Trial of Org 10,172 in Acute Stroke Treatment.
Cognitive Impairment at Different Stages After AIS
| At 2 Weeks n/N (%) | At 3 Months n/N (%) | At 12 Months n/N (%) | |
|---|---|---|---|
| MoCA&≦22 | 1274/2432(52.38) | 749/2107(35.55) | 456/1335(34.16) |
| MoCA&< 26 | 1841/2432(75.70) | 1230/2107(58.38) | 753/1335(56.40) |
| Visuospatial/executive abnormal# | 1905/2414(78.91) | 1525/2077(73.42) | 918/1310(70.08) |
| Naming abnormal# | 744/2428(30.64) | 444/2103(21.11) | 248/1327(18.69) |
| Attention abnormal# | 1098/2428(45.22) | 773/2106(36.70) | 445/1332(33.41) |
| Language abnormal# | 1433/2425(59.09) | 1173/2092(56.07) | 740/1324(55.89) |
| Abstraction abnormal# | 1359/2416(56.25) | 915/2048(44.68) | 562/1302(43.16) |
| Delayed recall abnormal# | 2156/2413(89.35) | 1714/2057(83.33) | 1083/1308(82.80) |
| Orientation abnormal# | 912/2426(37.59) | 491/2104(23.34) | 302/1334(22.64) |
Notes: &MoCA indicates Montreal Cognitive Assessment. #“abnormal” is defined as the total score of this cognitive item in MoCA scale is deducted by 1 point and above.
Figure 3The longitudinal changes of cognitive impairment at each follow-up point. The figure showed the longitudinal changes of cognitive impairment at each follow-up point. This included the number of patients who actually completed the follow-up evaluation of the scale and their proportion. The number of unfinished follow-ups was not shown in the figure.
Abbreviations: CI, cognitive impairment; NCI, no cognitive impairment.
The Percentage of Improved Patients for Each Abnormal Cognitive Item in MoCA Scale at 3-Month (3m) and 12-Month (12m) Follow-Up
| Improved& n/N# (%) (at 3m vs at 2w) | Improved& n/N# (%) (at 12m vs at 2w) | Improved& n/N# (%) (at 12m vs at 3m) | |
|---|---|---|---|
| Visuospatial/executive | 735/1609(45.68) | 500/1010(49.50) | 308/908(33.92) |
| Naming | 387/643(60.19) | 270/406(66.50) | 127/266(47.24) |
| Attention | 559/941(59.40) | 414/600(69.00) | 251/452(55.53) |
| Language | 461/1204(38.29) | 340/764(44.50) | 252/703(35.85) |
| Abstraction | 519/1125(46.13) | 393/714(55.04) | 172/519(33.14) |
| Delayed recall | 954/1814(52.59) | 691/1166(59.26) | 387/1028(37.65) |
| Orientation | 573/775(73.94) | 388/506(76.68) | 187/307(60.91) |
Notes: &“Improved” is defined as “the total score of this cognitive item is abnormal at 2w or 3m, but increased by 1 point and above at a later time point (3m or 12m)”. #N= the total number of patients who were abnormal at an earlier time point (2w or 3m) and completed follow-up at a later time point (3m or 12m). #n=Among N, the number of patients who were improved at a later time point (3m or 12m).